Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

61.70 +2.63 (+4.45%)
Streaming Delayed Price Updated: 12:40 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Why CRISPR Therapeutics Stock Fell 10.4% Last Month
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading. 
Via The Motley Fool
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
3 Explosive Biotech Stocks That Could 10X in 10 Years
They're leaders in therapeutic areas with massive growth potential. 
Via The Motley Fool
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Analyzing CRISPR Therapeutics's Unusual Options Activity
Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus... 
Via Benzinga
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover. 
Via The Motley Fool
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech. 
Via The Motley Fool
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
A crowded field could take years to thin out. 
Via The Motley Fool
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics
Currently trading at a very reasonable multiple, CRSP stock is an undeniable buy. 
Via InvestorPlace
Why CRISPR Therapeutics Stock Fell 25.2% in July
The stock dropped roughly $40 per share over the course of the month. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
Better Buy: Vertex vs. CRISPR
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run. 
Via The Motley Fool
CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today
Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate. 
Via InvestorPlace
Why CRISPR Therapeutics' Stock Is Trading Higher Today
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over... 
Via Benzinga
Why CRISPR Therapeutics' Stock Is Trading Higher Today
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect... 
Via Benzinga
Crispr Therapeutics Represents the Best of Emerging Biotechnology
CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks. 
Via InvestorPlace
Is CRISPR Therapeutics a Millionaire-Maker Stock?
It's already well on its way, but the road ahead will be long. 
Via The Motley Fool
Topics Initial Public Offering
3 Things About CRISPR Therapeutics That Smart Investors Know
The company is on track to be the first to market with a gene-editing therapy for blood disorders. 
Via The Motley Fool
Crispr Therapeutics Has Bullish DNA
Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning. 
Via InvestorPlace
Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?
Ethical concerns will likely dog CRISPR Therapeutics stock, especially with the present social awakening. 
Via InvestorPlace
Topics Economy
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Group Inc (NYSE: BX) very much. He keeps buying Wynn Resorts, Limited (NASDAQ: WYNN) for... 
Via Benzinga
How Investors Can Own A Piece Of Tesla, Shopify, CRISPR Therapeutics
Investing in the ARK Innovation ETF (NYSE:ARKK) is the ... 
Via Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
There are still some key unanswered questions for the biotech's promising gene-editing therapy. 
Via The Motley Fool
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.